Illustrative

Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC

AJMC·Jul 31

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Taletrectinib has been recommended in nccn guidelines for patients with ros1-positive non-small cell lung cancer. This recommendation suggests that taletrectinib is now considered a treatment option for this specific type of cancer. The guidelines indicate that taletrectinib is suitable for ros1-positive nsclc.

Full coverage

NCCN Guidelines Recommend Taletrectinib for ROS1+ NSCLC Subtype

CancerNetwork·Apr 28

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

PR Newswire·Apr 27

David Hung's Nuvation Bio wins FDA approval for Ibtrozi to challenge Pfizer, BMS and Roche in lung cancer field

Fierce Pharma·Jun 11

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

BioSpace·Aug 8

View original report at AJMC ↗

Fetching the latest headlines…

Taletrectinib Recommended in NCCN Guidelines for ROS1-Positive NSCLC

Full coverage

NCCN Guidelines Recommend Taletrectinib for ROS1+ NSCLC Subtype

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

NCCN CNS Guidelines Updated to Include Taletrectinib for ROS1+ NSCLC

NCCN Guidelines Now Recommend Taletrectinib for ROS1+ NSCLC

Navigating the Latest Guidelines for ROS1+ NSCLC

Selecting First-Line Therapy for ROS1 Fusion–Positive NSCLCs

David Hung's Nuvation Bio wins FDA approval for Ibtrozi to challenge Pfizer, BMS and Roche in lung cancer field

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update